

Autoimmune Disorder

An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03202368 2016-002716-41
ML39425

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter, interventional, open-label, long-term extension study of Study WA28119 (NCT01791153) to evaluate the long-term safety of SC tocilizumab in participants with GCA who subsequently have flare or persisting disease activity. A maximum of 11 participants from six centers in France that participated in the WA28119 study will be enrolled. The entire study duration is anticipated to be approximately 160 weeks.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03202368 2016-002716-41 ML39425
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 50 Years

Healthy Volunteers
No
